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Cryptosporidium parvum, one of the most important causative organisms of human diarrheas during childhood, contains a
monomeric DNA-topoisomerase IB (CpTopIB) in chromosome 7. Heterologous expression of CpTopIB gene in a budding yeast
strain lacking this activity proves that the cryptosporidial enzyme is functional in vivo. The enzymatic activity is comprised in a
single polypeptide, which contains all the structural features deﬁning a fully active TopIB. Relaxation activity of the yeast extracts
was detected only when CpTopIB ORF was expressed in a yeast expression system showing time and protein dependence under
steady state kinetic conditions. The susceptibility of CpTopIB-transformed yeast to the irreversible inhibitor camptothecin and its
water-soluble derivatives (topotecan and SN-38) was assessed.
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1.Introduction
Cryptosporidium parvum is one of the most important
causal agents of human diarrheas during childhood [1].
Infections occur by ingestion from poor quality supply
water contaminated with oocysts (resistance form of this
microorganism) [2]. In humans the infection is self-limiting
in immunocompetent individuals but may be fatal in
HIV-immunocompromised patients [3]. In ruminants the
infection is particularly severe in neonatal lambs, which
suﬀer from apathy, anorexia, abdominal cramps, diarrhoea,
and a large elimination of oocysts in faeces [4].
The high prevalenceof this disease may be a consequence
of the resistance of oocysts to chemical water treatments, to
the poor eﬃcacy of the current drugs used or the lack of
an eﬀective vaccine. Therefore, it is an essential integrated
approach in the management of this condition that involves
theuseofdisinfectants,hostimmune-reinforcingagents,and
new drugs [5, 6].
During last decade more than hundred antibiotics and
antiparasitic drugs have been tested against C. parvum
infections with little or no eﬀect [7]. Paromomycin, a poorly
absorbed aminoglycoside antibiotic, and more recently nita-
zoxanide were pointed as promising agents to treat cryp-
tosporidial infections in acquired immunodeﬁciency syn-
drome(AIDS)patients[8].Bothcompoundsshowedeﬃcacy
in animal models [9, 10] and paromomycin was prophylactic
in neonatal calves, lambs, and goats. On the other hand,
nitazoxanide—a nitazoxazole benzamide compound—has a
wide range of antimicrobial activity against helminthic para-
sites. More striking is the drastic reduction in the prevalence
of opportunistic Cryptosporidium spp. infections associated
to AIDS patients treated with highly active antiretroviral
therapy(HAART)[11].Therefore,thereisanurgentneedfor
novelcompoundsthateradicatetheseinfectionswithpooror
no side eﬀects on the host [12].
Enzymes responsible for DNA manipulation have been
studied for long as potential pharmacological targets in
proliferative processes such as microbial and parasitic infec-
tions and tumor processes. DNA topoisomerases (Top) are
enzymatic machines catalyzing changes in the topological
state of duplex DNA during replication, transcription,
recombination, and DNA repair processes. There are two
families and several subfamilies of these enzymes: Type I
DNA topoisomerases (TopI) are ATP-independent enzymes
with relaxation activity for both positively and negatively
supercoiled DNA [13, 14]. Type II DNA topoisomerases
(TopII) are multimeric proteins that hydrolyze ATP to
generate temporary DNA double-strand breaks followed
by passage and rejoining. TopII enzymes not only relax
positively supercoiled DNA but also knot/unknot and cate-
nate/decatenate close circular DNA [15].2 Journal of Biomedicine and Biotechnology
Many compounds have been screened against Top
enzymes, and some of them are being used nowadays.
Fluoroquinolones were successfully tested as inhibitors of
the DNA gyrases in bacteria and some of them are potent
antibiotics of choice [16]. On the other hand TopIB is
being targeted in the treatment of several tumor processes
(Pommier, 2006). Water-soluble derivatives of camptothecin
(CPT)—topotecan and the prodrug irinotecan—are part of
the current pharmacopoeia against certain types of cancers,
but the studies are much scarcer in relation to topoiso-
merasesinprotozoanparasites[17,18].Theamazingﬁnding
of a bi-subunit TopIB in Kinetoplastids [19]h a so p e n e da
new ﬁeld in the chemotherapy of these parasites, but little
is known about Top in apicomplexan. Only Plasmodium
falciparum TopIB (PfTopIB) has been cloned, functionally
expressed and targeted with CPT derivatives [20, 21].
An early report describing the cloning of a type II DNA
topoisomerase from C. parvum was published years ago [22]
but no further information about these enzymes has been
reported at present. In this paper we describe the functional
expressionofCpTopIBgenefromtheapicomplexanprotozoa
C. parvum, as well as the heterologous expression, kinetic
analysis of the recombinant enzyme and the inhibition by
CPT and analogues.
2.MaterialsandMethods
2.1. Reagents. DNA modiﬁcation and restriction enzymes
were procured from Roche (Basel, Switzerland) and Amer-
sham Biosciences. Pyrococcus furiosus (Pfu) polymerase was
from Stratagene (La Jolla, Calif, USA). Cell culture media,
chemicals and reagents were purchased from Sigma (St.
Louis, Mo, USA). Primers for PCR ampliﬁcation were from
Sigma Genosys (UK). CPT and SN-38 were from Tocris
(Tocris Bioscience, Ellisville, Mo, USA), topotecan from R&S
Pharmachem (Co. Ltd. China).
2.2. Yeast and Cryptosporidial Strains. C. parvum ooquistes
were kindly provided by Dr. Teresa G´ omez Mu˜ noz;
Dpt. Atenci´ on Sanitaria, Salud P´ ublica y Sanidad
Animal; Universidad Cardenal Herrera (CEU) Valencia
(Spain). For protein expression Saccharomyces cerevisiae
strains (a gift from Dr. MA Bjornsti, St. Jude Children’s
Research Hospital, Memphis, TN) EKY3 [MAT α ura3-
52 his3Δ200leu2 Δ1t r p 1Δ63 top1 Δ::TRP1] and MBY3
[MAT α ura3-52 his3Δ200 leu2 Δ1t r p 1 Δ63, top1 Δ::TRP1
rad52 Δ::LEU2], both deﬁcient in DNA topoisomerase I
activity, were used [23].
2.3. Cloning of Cryptosporidial DNA Topoisomerase I.
Cloning of C. parvum DNA-topoisomerase I (CpTopIB)
was performed by PCR ampliﬁcation using whole genomic
cryptosporidial DNA as template [24] and the primers
showed in Table 1. CpTopIB (GenBank accession number
XM-628497) gene, was ampliﬁed using Pfu-polymerase and
nucleotides, and the ampliﬁed band was loaded in a low-
melting gel agarose, electrophoresed and taken from the gel
for cloning. The 1923 nt ampliﬁed band was digested with
SmaI and HindIII and ligated to YCpGAL (Leu-) vector and
sequencedbeforeexpressioninaTopIB-deﬁcientyeaststrain.
2.4. Yeast Expression System. S. cerevisiae strain, EKY3
was transformed with diﬀerent constructs viz; wild type
(CpTopIB); R318A; K358A; R416A; H489A and Y600F, as
the diﬀerent point mutations, by electroporation [25]. The
GAL promoted expression vector carries the Leu- selectable
marker and is maintained by selection in synthetic complete
SC leu- medium. At least ﬁve independent clones were
selected from each transformation. After 6-hour induction
with2%galactoseinSCleu-raﬃnosemedium,thecellswere
harvested by centrifugation, washed, and resuspended in
TEEG buﬀer (50mM Tris-HCl pH 7.4, 1mM EDTA, 1mM
EGTA, 10% glycerol) supplemented with 0.2M KCl, and
protease inhibitors cocktail [1 × NaF, 1 × sodium bisulphite,
2 × Complete Mini (Roche Molecular Biochemicals)]. Cell
extracts were prepared by disruption with acid-washed
glass beads using a bead-beater chamber (5 cycles of 30
seconds on, 30 seconds oﬀ) according to a previously
described procedure [26]. Brieﬂy, cells were subjected to
one freeze/thaw cycle at –80◦C, lysed by vortexing with
425–600μm glass beads and the extracts were cleared by
centrifugation at 15000 xg for 30 minutes at 4◦C.
2.5. Protein Puriﬁcation. Puriﬁcation of CpTopIB was done
according to [27]. Brieﬂy, overexpressing yeast extracts were
loaded onto a phosphocellulose (P-11) column previously
equilibrated as manufacturer indications. The recombinant
proteins (wild-type CpTopIB and mutated forms) were
eluted at 4◦C with a discontinuous gradient of KCl (0.2,
0.4, 0.6, 0.8 and 1M) in TEEG buﬀer, supplemented with
0.1mg/mL sodium bisulphite, 0.8mg/mL NaF and the pro-
teaseinhibitorscocktail.Theactivefractionsweremixedwith
equal volume of 2M NH2SO4 a n dl o a d e do n t oap h e n y l -
sepharose column preequilibrated with TEEG containing
1MNH 2SO4 (Sigma-Aldrich, St. Louis, USA). The column
was eluted with a discontinuous inverse gradient of NH2SO4
(1, 0.8, 0.6, 0.4 and 0.2M). In order to reach an appropriate
concentrationforthediﬀerentinvitroassays,theeluatefrom
the phenyl-sepharose column was concentrated by Microcon
YM-30 (Millipore, Co, Ma, USA). Purity of the samples was
analyzed by SDS-PAGE. To store, 40% glycerol was added
t op r e s e r v et h ea c t i v i t ya n dk e e pi na−20◦Cf r e e z e r .P r o t e i n
concentration was determined colorimetrically [28].
2.6. DNA Relaxation Assays. CpTopIB activity was assayed
by the relaxation of a negatively supercoiled plasmid DNA.
The reaction mixture in a total volume of 20-μL contained
0.5μgo fs u p e r c o i l e dR FI( ΦX-174) DNA, 10 mM Tris-HCl
buﬀerpH7.5,5mMMgCl2,0.1mMEDT A,15μg/mLbovine
serum albumin, 50mM KCl, and 0.2μg puriﬁed protein. The
reaction mixtures were incubated for 30 minutes at 37◦C.
The enzyme reactions were digested with the addition of 2μg
of proteinase K, incubating for 1 hour and adding up to 1%
SDS. The extent of plasmid DNA relaxation was assessed by
electrophoresisina1%agarosegelin0.1MTrisborateEDTA
buﬀerpH8.0at2V/cmfor14hours.ThegelswerevisualizedJournal of Biomedicine and Biotechnology 3
Table 1: Sequences of the primers used in this study to clone and to mutate CpTopIB.
Specimen Primers (5 -3 )
Wild type FW ATA AGA ATG CGG CCGCAT GGC ATC AGC TAC GGA TTC
RV GGA CTAGTT TAA AAT GAA AAA TCT GAT CTC G
R318A FW GAT TTT TTA GCT TTG GCG GTC GGA GGA GAA AAA G
RV C TTT TTC TCC TCC GAC CGC CAA AGC TAA AAA ATC
K358A F W C T TT A GA T TT T TT G GGCG CGG ATT CAA TTC GAT AC
RV GT ATC GAA TTG AAT CCG CGC CCA AAA AAT CTA AAG
R416A F W C TG C CA A GGT AT T TGCG ACA TTC AAT GCA TC
RV GA TGC ATT GAA TGT CGC AAA TAC CTT GGC AG
H489A FW GCG ATA TTA TGT AAC GCG CAG AGA TCA GTT CC
RV GG AAC TGA TCT CTG CGC GTT ACA TAA TAT CGC
Y600F FW CA TCG AAG ATT AAC TTTATG GAT CCC AGG ATT TC
RV GA AAT CCT GGG ATC CAT AAAGTT AAT CTT CGA TG
under UV illumination after being stained with ethidium
bromide (0.5mg/mL) and a posterior electrophoresis in
the presence of 0.1mg/mL ethidium bromide, in order to
separate the nicked DNA from the relaxed topoisomers.
2.7. In Vitro Cleavage Assay. To 0.5 μgs u p e r c o i l e dR FI
DNA, in a total volume of 20μL cleavage buﬀer (35mM
Tris HCl, pH 7.5, 50mM KCl, 3mM β-mercaptoethanol,
0.1mM EDTA, and 50mg/mL BSA), was added a solution
of the appropriate drug dissolved in DMSO or water (ﬁnal
concentration of DMSO in the incubation mixture must
not exceed 1%). The DNA-cleavage reaction was initiated
by the addition of 2 units of CpTopIB puriﬁed as above.
After incubation for 30 minutes at 37◦C, the cleavable
complex was trapped by the addition of 2μL 10% SDS,
followed by the digestion with proteinase K for a further
30 minutes period at 45◦C. The mixture was puriﬁed with
phenol/chloroform and electrophoresed in a 0.9% agarose
gel containing ethidium bromide (0.5μg/mL). The increase
of nicked DNA was estimated as drug-induced CpTopIB-
mediated DNA cleavage.
2.8. Site-Directed Mutagenesis. The procedure to obtain the
mutated genes was developed according to the QuickChange
method, following the instructions procedure; the ORF
encoding CpTopIB gene was mutated and subcloned in
the YCpGAL(Leu-) vector. Figure 1 describes the distinct
mutations performed on CpTopIB.
The sequence of the primers used and their codon
changes are listed in Table 1. The PCR reaction contained
20ng of plasmid YCp-CpTopIB as template depending on
the diﬀerent mutations, 1μM of each oligonucleotide, 10μM
dNTPs, 5μL of 10 × Pfu-buﬀer, and 2.5 units of Pfu-
polymerase for a total volume of 50μL. Reactions were
carried out in a Mastercycler gradient thermocycler (Eppen-
dorf) as follows: a 5-minute ﬁrst step at 94◦C, followed by
an ampliﬁcation cycle at 95◦Cf o r1m i n u t e ,6 0 ◦Cf o r1m i n
and 72◦C for 1 minute; repeated for 16 times. Mutants were
sequenced (Sistemas Genomicos, Spain) in order to conﬁrm
the absence of undesirable additional mutations.
2.9. In Vivo Sensitivity to CPT. Sensitivity of the MBY3
yeast cell lines transformed with va s CpTopIB constructs
to CPT was determined, as described earlier. The individual
transformed yeast cell lines grown in SC leu- medium
plus dextrose were serially diluted 10-fold and 5-μL of
each culture were spotted onto selective SC leu-agar plates
supplemented with 25mM HEPES, pH 7.2, 2% dextrose or
galactose, supplemented with 30μM CPT in a ﬁnal 0.25%
DMSO. The controls plates without the drug contained
0.25% DMSO. Viability (growth) of yeast cells was scored, as
per the size of the culture spot, following incubation at 30◦C
for 24 hours.
3. Results
3.1. Cryptosporidium parvum Topoisomerase IB. The active
form of CpTopIB (GenBankTM accession number XM-
628497) is the expression product of a single 1923 bp ORF.
The expressed polypeptide corresponding to the putative
CpTopIB is constituted by 641 amino acids with a predicted
molecular mass of 74.7 kDa and a pI of 8.7, showing a 60%
identity to human DNA topoisomerase IB (hTopIB) (Gen-
BankTM accession number J03250), 75% identity to baker
yeast’s (yTopIB) (GenBankTM accession number K03007),
and 99.8% of identity with C. homini. The protein is much
shorter than human’s (765 amino acids) and baker yeast’s
(769 amino acids), but contains all the recognizable domains
of a canonical TopIB protein. A recombinant active enzyme
was obtained by cloning the PCR-ampliﬁed band into the
yeast expression vector YCp-GAL(Leu-) driven by GAL1
promoter and expressed in a TopIB-lacking yeast system
(EKY3).
Figure 1(a)showsasequencealignmentofCpTopIB with
its homologous from human, P. falciparum, and the budding
yeast Saccharomyces cerevisiae showing that, as expected,
CpTopIB contains a putative nonconserved N-terminal4 Journal of Biomedicine and Biotechnology
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Figure 1: Multiple amino acid sequence alignments of CpTopIB. The amino acid sequences predicted for the C. parvum, P. falciparum,
S. cerevisiae, and human topoisomerases were aligned using the ClustalX multiple sequence alignment program. Symbols:“ ∗” represents
identical or conserved residues in all sequences in the alignment, “:” conserved substitutions and “.” semiconserved substitutions. Complete
genomic sequences of MAT proteins are available in GenBank, for S. cerevisiae accession number (K03007), P. falciparum (X83758), human
(J-03250), and C. parvum (XM-628497). Arrowheads represent the points where a protein domain starts.
domain (start-Met-Gly 42), a conserved core domain (Ile-
43-Val-492), and the C-terminal domain, (Thr-590-Phe-
641) which shows high homology with other eukaryotic
C-terminal ends [29]( Figure 1(b)). This region includes a
phylogenetically conserved “SKINY” signature in which Tyr-
600 (Tyr-723 in the human enzyme) plays role in DNA
cleavage. The C-terminal domain is connected to the core
by a poorly conserved coiled-coil putative linker (Val-493-
Val-589). The putative cryptosporidial core domain has high
homology with the one from the human enzyme (Gln 33-
Ser 456) and other species, and it includes all the amino
acid composing the so-called catalytic tetrad involved in the
relaxing activity; Arg-318 (Arg-488 in the human enzyme),
Lys-358 (Lys-532 in the human enzyme); Arg-416 (Arg-590Journal of Biomedicine and Biotechnology 5
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Figure 2: Expression and activity of CpTopIB and mutants into an EKY3 Top-IB-deﬁcient yeast strain. (a) SDS-PAGE from the puriﬁed
yeast extracts expressing wild type CpTopIB and the point mutations carried out into catalytic tetrad amino acids (R318A, K358A, R416A,
and H489A) as well as the active site (Y600F). (b) Dilution assay 2-fold serial dilutions of wild type CpTopIB were assayed in a plasmid DNA
relaxation assay for 30 minutes at 37◦C (as described under “Materials and Methods”). (c) Equal concentrations of CpTopIB were incubated
stepwise for 10 seconds to 30 minutes in a plasmid DNA relaxation assay. Reaction products were resolved in agarose gel and subsequently
visualized by ethidium bromide staining. The reactions were incubated at 30◦C for 30 minutes and then stopped with a mixture of 1% SDS
and 6.1μg of proteinase K. The reaction products were resolved in a 1% agarose gel and visualized by ethidium bromide staining. N: nicked;
Sc: supercoiled DNA, R: relaxed DNA.
in the human enzyme) and His-489 (His 632 in the human
protein).
When CpTopIB gene was expressed in the yTopIB-
defective EKY3 yeast strain, using the YCp-GAL(Leu-) vec-
tor, signiﬁcant relaxation activity was detected. Yeast extracts
were pooled and puriﬁed as described above (Figure 2(a)).
Puriﬁed CpTopIB was used for kinetic characterization.
Relaxation activity of the supercoiled Rf I close circular
DNA from the virus ΦX-174, was measured as a function of
protein concentration (Figure 2(b))a n dt i m e( Figure 2(c)).
Using 2 units of puriﬁed CpTopIB and 0.3μgo fs u p e r c o i l e d
DNA substrate, a distributive relaxation activity with many
relaxed topological isomers was obtained as early as 5
seconds, completing the process in 1 minute. Two-fold
serially diluted CpTopIB-transformed EKY3 yeast extracts
were assayed for relaxation activity (Figure 2(b)) starting
from 0.2μg protein (left lane). Signiﬁcant activity was found
after six 2-fold dilutions (0.03μg protein) but no visible
topoisomers were detectable beyond.
We further studied the relative in vitro DNA-cleavage
potentials of CPT, topotecan, and SN-38—the active
metabolite of irinotecan hydrolysis by cellular esterases
[30]—at 10 and 100μM ﬁnal concentrations. The capability
of these compounds to stabilize DNA-cleavable-complexes
was determined by agarose gel electrophoresis, followed by
SDS and proteinase K treatments that allow denaturation6 Journal of Biomedicine and Biotechnology
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Figure 3: Eﬀects of CPT, topotecan, and SN-38 on the stabilization
of covalent TopIB-DNA cleavable complexes. Standard cleavage
assay (Material and Methods) were carried out with ﬁnal concen-
trations of CPT, topotecan, and SN-38 of 10 and 100μM. CPT was
added at a ﬁnal concentration of DMSO of 1%. The reactions were
incubated at 30◦C for 30 minutes and then stopped with a mixture
of 1% SDS and 6.1μg of proteinase K. The reaction products were
resolved in a 1% agarose gel and visualized by ethidium bromide
staining. Sc: supercoiled DNA, R: relaxed DNA, N: nicked DNA.
and proteolysis of the binary complex, producing an increase
innickedDNA(Figure 3).Thereisadose-dependentnicked-
DNA increase for CPT and topotecan, but it could not be
found for the irinotecan metabolite SN-38.
3.2. Site-Directed Mutagenesis Studies. T h er o l eo ft h ea m i n o
acids of the catalytic tetrad was analyzed by site-directed
mutagenesis, studying the relaxation activity of the mutated
proteins. Based on these analogies, we replaced the residues
sited at the core domain by the neutral amino acid alanine,
which is not protonable at physiological pH, preventing
the electrostatic contributions in substrate catalysis and
hydrogen bonding (mutations R318A, K358A, R416A and
H489A). On the other hand Tyr-600, placed at the C-
terminal end, which aligns with a homologous Tyr at posi-
tion 723 in the human enzyme, was replaced by Phe, which
is sterically homologous but lacks the ability to cleave DNA
(mutation Y600F). All these mutations were created in the
pSKvector,carriedtotheyeastYCp-GAL(Leu-)plasmid,and
heterologously expressed in the TopIB-deﬁcient yeast system
(EKY3).Figure 2(b)comparestheresidualrelaxationactivity
of these mutants with the one found in the recombinant
wild-type enzyme. As expected, none of the mutants of the
active site created, displayed any signiﬁcant ability to relax
supercoiled DNA under standard assay conditions, using
undiluted extracts (0.2μg protein).
3.3. Topoisomerase-Deﬁcient Yeast Sensitization to CPT.
CpTopIB is conserved in terms of reaction mechanism and
drug sensitivity. The heterologous expression of the wild
type dimeric enzyme into a topoisomerase-deﬁcient yeast
strain (top1Δ) and defective in double-strand breaks repair
(rad52Δ); MBY3 was able to confer sensitivity to 30μMC P T
when cultures where induced with 2% galactose (Figure 4).
The site-directed mutants prepared previously were
transfected to the MBY3· yeast-deﬁcient strain plated and
induced with 2% galactose in absence and presence of 30μM
CPT. Pictures of Figure 4 show that none of the catalytic
amino acids (R318A, K358A, R416A, and H489A), nor
the active site mutant (Y600F), conferred susceptibility to
camptotecin to the transformed yeasts. In addition CpTopIB
MBY3—transformed yeast induced a signiﬁcant drop in
the number of viable cells when treated with CPT both in
time course (Figure 5(a)) and dose-response (Figure 5(b))
experiments, thus showing the requirement of an active Top
enzyme to be inhibited by the drug.
4. Discussion
There is no eﬀective pharmacological treatment to eradicate
cryptosporidiosis. It is well established that this disease
can be fatal only when the immune system is challenged.
Several antibiotics and antiprotozoal agents have been
clinically or experimentally assessed, with very limited or
no success. However, some drugs may be overviewed along
with some new approaches attempted for new drug design
and development against cryptosporidiosis. There is an
increasing body of evidence that Cryptosporidium oocysts
exposed to UV light are not able to regain the infectivity
previous to exposure. Rochelle and coworkers explained
that the mechanism of nucleotide excision repair (NER) is
not suﬃcient to restore the damage caused to DNA due
to mutations or the absence of repair genes [31]. Many
Top inhibitors are DNA-damaging agents, causing stable
single (SSB) and double strand breaks (DSB) [32]. This
particular feature and the fact that these compounds are
being used eﬀectively as antineoplasic agents make Top
enzymes promising targets for chemotherapy intervention
against cryptosporidial infections.
We have cloned and functionally expressed the predicted
CpTopIB gene (GenBank XM-628497), with C. parvum
genomic DNA as a template. Like trypanosomatids, attempts
to express this ORF in a routine bacterial expression system
were not successful and a top-deﬁcient yeast strain was
required for this purpose [33]. Heterologous expression of
CpTopIB-transformed S. cerevisiae strain under galactose
pressure produced a single prominent band of 76kDa,
which is consistent with the estimated molecular mass of
the putative ORF. Puriﬁed yeast extracts by a conventional
low-pressure liquid chromatography procedure derived in a
highly enriched solution of CpTopIB that was used to relax
supercoiled DNA.
CpTopIB contains all the structural and enzymatic fea-
tures described for all TopIB enzymes in a single polypeptide
that relaxes supercoiled DNA distributively. The enzyme was
targeted by CPT and the water-soluble derivative topotecan,
which established irreversible bonds with DNA, but not by
the irinotecan metabolite SN38 that surprisingly was not
able to cleave DNA at the concentrations used. Site-directed
mutagenesis of the amino acids composing the catalytic
tetrad in the putative core domain yielded in no enzymatic
activity at all, as well as the point substitution of the cleavingJournal of Biomedicine and Biotechnology 7
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Figure 4: Expression of CpTopIB gene induces sensitivity to CPT-resistant yeast strain MBY3 (rad52Δ). Exponentially growing cells in
dextrose, transformed with vectors carrying the cryptosporidial wild type and point mutations driven by GAL1 promoter, were serially
10-fold diluted starting from OD595 = 0.5. Five microliters were spotted on selective media under induced (2% galactose) conditions in the
presence or absence of 30μM CPT. All plates contained 0.375% DMSO. Empty assay was performed under similar assay conditions but
expression the YCpGAL(leu-) vector without any insert.
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Figure 5: Yeast cell sensitivity to CPT depends on the expression of an active DNA topisomerase I from Cryptosporidium spp. (a) MBY3
yeast cells were transformed either with the YCp-GAL, vector empty, or carrying the wild type CpTopIB, in the presence or absence of 50μM
CPT (dissolved into 1% DMSO) at t = 0. After 3, 6, 24, and 48 hours aliquots were serially diluted and plated in Petri dishes containing
yeast culture medium plus 1% dextrose. (b) Dose-response curve showing the inhibitory eﬀect of CPT on yeast cell growing after 24 hours
galactose induction. The number of colonies were determined at 30◦C and plotted relative to the number of colonies obtained at t = 0. Data
are the average of ﬁve diﬀerent experiments.
Tyr-600 by Phe. All these results supported the existence of a
conserved active centre that matched well with that reported
in the human enzyme [29, 34].
Only one apicomplexan TopIB has been studied at
present. Riou and coworkers, puriﬁed and characterized
PfTopIB from infected erythrocytes (Riou et al., [35]). Like
C. parvum, plasmodial enzyme is a monomeric protein of
104kDa corresponding to a peptide of 839 amino acids
which gene is located at chromosome 5 of the plasmodial
genome, and it is developmentally regulated during the8 Journal of Biomedicine and Biotechnology
diﬀerentstagesof Plasmodiumlifecycle[21].Inaddition, the
enzyme is eﬀectively targeted by CPT that induces cleavable
complexes with DNA in vitro [17].
In conclusion, there is an increasing resistance of C.
parvum to such a broad range of chemotherapeutic agents,
some of which are eﬀective against other apicomplexan
parasites. This might be related to the intracellular stages
of the life cycle that are practically engulfed inside the host
cytoplasm. Therefore, there is an urgent need of novel targets
fordrugscreening.TheabovementionedresultsshowthatC.
parvum contains an active TopIB enzyme that is presumable
involved in resolving structural problems in DNA during
replication, transcription, and repair processes. Unlike other
protozoa, the enzyme comprises a unique protein encoded
by a single gene, which contains all the structural features
deﬁning a fully active TopIB. Understanding of distinct
molecular characteristics of the CpTopIB and regulation of
expression of the enzyme during parasite life cycle may
be useful for development of novel selective inhibitors of
CpTopIB as promising anticryptosporidial agents.
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